Cargando…

Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder—A Narrative Review

The estimated rate of treatment-resistant major depressive disorder (TRD) remains higher than 30%, even after the discovery of multiple classes of antidepressants in the last 7 decades. Toludesvenlafaxine (ansofaxine, LY03005, or LPM570065) is a first-in-class triple monoaminergic reuptake inhibitor...

Descripción completa

Detalles Bibliográficos
Autor principal:	Vasiliu, Octavian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051807/ https://www.ncbi.nlm.nih.gov/pubmed/36986510 http://dx.doi.org/10.3390/ph16030411

Ejemplares similares

Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor
por: Zhu, Haibo, et al.
Publicado: (2021)

Esketamine for treatment‑resistant depression: A review of clinical evidence (Review)
por: Vasiliu, Octavian
Publicado: (2023)

The effect of triple reuptake inhibitor toludesvenlafaxine on neurological function in cerebral ischemic rats
por: Sun, Xiaohui, et al.
Publicado: (2023)

Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second‑generation antipsychotics (Review)
por: Vasiliu, Octavian
Publicado: (2023)

Third generation cognitive-behavioral therapies for major depressive disorder- a literature review
por: Vasile, D., et al.
Publicado: (2021)

At the Crossroads between Eating Disorders and Body Dysmorphic Disorders—The Case of Bigorexia Nervosa
por: Vasiliu, Octavian
Publicado: (2023)

State of the Art and Challenges in Epilepsy—A Narrative Review
por: Manole, Aida Mihaela, et al.
Publicado: (2023)

Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis
por: Kishimoto, Taishiro, et al.
Publicado: (2023)

Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents
por: Vasiliu, Octavian
Publicado: (2022)

Orphan Drugs in Neurology—A Narrative Review
por: Sirbu, Carmen Adella, et al.
Publicado: (2023)

Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents
por: Vasiliu, Octavian
Publicado: (2022)

Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability
por: Kirino, Eiji
Publicado: (2012)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011)

The pharmacogenetics of the new-generation antipsychotics – A scoping review focused on patients with severe psychiatric disorders
por: Vasiliu, Octavian
Publicado: (2023)

The current state of research for psychobiotics use in the management of psychiatric disorders–A systematic literature review
por: Vasiliu, Octavian
Publicado: (2023)

M193. CHANGES IN THEORY OF MIND DETECTED IN SCHIZOPHRENIA SPECTRUM DISORDERS- A LITERATURE REVIEW
por: Vasiliu, Octavian
Publicado: (2020)

Therapeutic management of buying/shopping disorder: A systematic literature review and evidence-based recommendations
por: Vasiliu, Octavian
Publicado: (2022)

Mindfulness-based cognitive therapy for major depressive disorder- a literature review
por: Vasile, D., et al.
Publicado: (2021)

Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders
por: Belendiuk, Katherine A, et al.
Publicado: (2015)

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary
por: Ball, Susan G, et al.
Publicado: (2013)

The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis
por: Meeker, Amanda S, et al.
Publicado: (2015)

Is There an Association Between Migraine and Major Depressive Disorder? A Narrative Review
por: Jahangir, Saira, et al.
Publicado: (2020)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
por: Zhang, Xiao-Fei, et al.
Publicado: (2015)

Levomilnacipran for the treatment of major depressive disorder: a review
por: Asnis, Gregory M, et al.
Publicado: (2015)

Anti-Inflammatory Treatment Efficacy in Major Depressive Disorder: A Systematic Review of Meta-Analyses
por: Simon, Maria S, et al.
Publicado: (2023)

Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
por: Martin, Vincent, et al.
Publicado: (2020)

Efficacy and tolerability of agomelatine in the treatment of depression
por: Plesničar, Blanka Kores
Publicado: (2014)

Current Trends and Perspectives in the Immune Therapy for Substance Use Disorders
por: Vasiliu, Octavian
Publicado: (2022)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
por: Huang, Qunlian, et al.
Publicado: (2016)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Vasiliu, Octavian
Publicado: (2021)

An integrative model as a step toward increasing the awareness of eating disorders in the general population
por: Vasiliu, Octavian
Publicado: (2023)

T196. THERAPEUTIC MANAGEMENT IN MULTIPLE SCLEROSIS AND SCHIZOPHRENIA SPECTRUM DISORDERS DUAL DIAGNOSIS
por: Vasiliu, Octavian
Publicado: (2020)

Therapeutic management of major depression and psoriazis dual diagnosis
por: Vasiliu, O.
Publicado: (2021)

Digital Phenotyping for Differential Diagnosis of Major Depressive Episode: Narrative Review
por: Ettore, Eric, et al.
Publicado: (2023)

Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized–controlled trials comparison with venlafaxine
por: Maneeton, Narong, et al.
Publicado: (2013)

Efficacy and Safety of Topical Morphine: A Narrative Review
por: Nosek, Krzysztof, et al.
Publicado: (2022)

Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis
por: Li, Zejun, et al.
Publicado: (2023)

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder
por: Martinez, James M, et al.
Publicado: (2015)

Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
por: Wade, Alan G, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1dc8fj9u1oeb8d5l2vhspu79rq